News
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das erste Halbjahr 2022 und gibt Update zur Unternehmensentwicklung
DGAP-News: Abivax: Phase-2b-Studienergebnisse mit Obefazimod (ABX464) in Colitis ulcerosa in Fachzeitschrift „The Lancet Gastroenterology & Hepatology” veröffentlicht
DGAP-News: Abivax gibt erfolgreiche, überzeichnete cross-over Finanzierung über insgesamt EUR 49,2 Mio. mit hochkarätigen US-amerikanischen und europäischen Biotech-Investoren bekannt
DGAP-News: Abivax gibt Änderung seiner Führungsstruktur/Governance im Aufsichtsrat bekannt
DGAP-News: Abivax erhält Genehmigung des US Institutional Review Boards für das Phase-3-Studienprogramm mit Obefazimod zur Behandlung von Colitis ulcerosa
BOIRON : Projected timetable of the next publications and events 2023
The projected timetable of the next publications and events for the year 2023 is the following one:
Publications Date of publication (after market closing) Information meetings
The Bastide Group enters the respiratory care devices market in Italy
Caissargues, July 18, 2022
The Bastide Group announces the acquisition of a majority stake in Oxystore, a company based near Milan, Italy. Oxystore specializes in home diagnosis and online sales of
DGAP-News: Abivax gibt die Ergebnisse seiner am 9. Juni abgehaltenen ordentlichen und außerordentlichen Jahreshauptversammlung bekannt
DGAP-News: Abivax: Phase-2a-Studienergebnisse mit Obefazimod (ABX464) in RA in Fachzeitschrift “Annals of the Rheumatic Diseases” veröffentlicht und für Präsentation auf dem EULAR-Kongress ausgewählt
DGAP-News: Abivax kündigt ordentliche und außerordentliche Jahreshauptversammlung für den 9. Juni 2022 an und stellt Sitzungsunterlagen bereit
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed
Caissargues, May 12, 2022
In €k 2020-2021 2021-2022 Change 3rd quarter revenue 111,669 118,446 +6.1% 9-month revenue 333,033 341,491 +2.5%
Group
DGAP-News: Abivax veröffentlicht Referenzdokument 2022 'Document d'Enregistrement Universel'
BOIRON : 2022 first quarter sales
(Unaudited data)
In thousands of euros 2022 2021 Variation at current exchange rates Variation at constant exchange rates France 77,055 51,518 +49.6% +49.6% Europe
BOIRON : 2021 results
The Board of Directors of BOIRON, at its meeting on March 9, 2022 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31
BOIRON : 2021 sales
(Unaudited data)
QUARTERLY ACTIVITY IN 2021 (VARIATION AT CURRENT EXCHANGE RATES)
in thousands of euros 1st quarter 2nd quarter 3rd quarter 4th quarter 2021 2020 Var. 2021
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for
Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm:
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
Transgene Reports Business Update and Q3 2021 Financial Position
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities